Table 2.
Differences in clinical laboratory characteristics between DPHCC, NCPHCC and ICC groups
| Variables | DPHCC(a) (n = 27) | NCPHCC(b) (n = 113) | ICC(c) (n = 68) |
P value (a vs b) |
P value (a vs c) |
|---|---|---|---|---|---|
| Sex | 0.000 | 0.920 | |||
| Male | 12(44.4%) | 104(92.0%) | 31(45.6%) | ||
| Female | 15(55.6%) | 9(8.0%) | 37(54.4%) | ||
| Age(years) | 54.78 ± 10.68 | 58.17 ± 10.31 | 59.57 ± 10.72 | 0.088 | 0.052 |
| AFP > 20ug/L | 18(66.7%) | 60(53.1%) | 4(5.9%) | 0.202 | 0.000 |
| CA199 > 37U/mL | 3(11.1%) | 11(9.7%) | 46(67.6%) | 1.000 | 0.000 |
| CEA > 5 ug/L | 5(18.5%) | 11(9.7%) | 25(36.8%) | 0.341 | 0.084 |
| CA125 > 35U/mL | 4(14.8%) | 19(16.8%) | 38(55.9%) | 1.000 | 0.000 |
| HBV infection | 1.000 | 0.000 | |||
| Yes | 26(96.3%) | 108(95.6%) | 10(14.7%) | ||
| No | 1(3.7%) | 5(4.4%) | 58(85.3%) | ||
| hepatocirrhosis | 0.297 | 0.000 | |||
| Yes | 19(70.4%) | 90(79.6%) | 9(13.2%) | ||
| No | 8(29.6%) | 23(20.4%) | 59(86.8%) | ||
| MVI | 0.601 | 0.020 | |||
| Yes | 5(18.5%) | 14(12.4%) | 30(44.1%) | ||
| No | 22(81.5%) | 99(87.6%) | 38(55.9%) | ||
| PVTT | 0.214 | 0.064 | |||
| Yes | 4(14.8%) | 5(4.4%) | 23(33.8%) | ||
| No | 23(85.2%) | 108(95.6%) | 45(66.2%) | ||
| Lymphatic metastasis | 0.364 | 0.000 | |||
| Yes | 4(14.8%) | 8(7.1%) | 40(58.8%) | ||
| No | 23(85.2%) | 105(92.9%) | 28(41.2%) | ||
| Distant metastasis | 0.214 | 0.064 | |||
| Yes | 4(14.8%) | 5(4.4%) | 23(33.8%) | ||
| No | 23(85.2%) | 108(95.6%) | 45(66.2%) |